Comparative Pharmacology
Head-to-head clinical analysis: GRIS PEG versus NOXAFIL POWDERMIX KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRIS PEG versus NOXAFIL POWDERMIX KIT.
GRIS-PEG vs NOXAFIL POWDERMIX KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Griseofulvin binds to and disrupts microtubule function by interfering with the polymerization of tubulin, thereby inhibiting fungal cell mitosis and nucleic acid synthesis.
Posaconazole inhibits fungal CYP450-dependent 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
For tinea capitis and other dermatophyte infections: 500 mg oral daily as a single dose or in divided doses. For more severe infections, up to 1 g daily in divided doses.
300 mg (one 300-mg vial) intravenously twice on day 1, then 300 mg intravenously once daily starting on day 2. Alternatively, oral suspension: 200 mg (10 mL) three times daily. For prophylaxis, IV: 300 mg twice on day 1, then 300 mg once daily; oral: 200 mg three times daily.
None Documented
None Documented
Terminal elimination half-life 14-24 hours. With continuous therapy, time to steady-state is ~3-5 days.
The terminal elimination half-life is approximately 27 hours (range 20-66 hours) in healthy subjects, allowing for once-daily dosing after steady state.
Primarily renal (as glucuronide conjugates): ~80%; fecal/biliary: ~10-15%; unchanged drug <1%.
Posaconazole is primarily excreted in the feces (77%) as unchanged drug, with renal excretion accounting for 14% of the dose (primarily as glucuronide conjugates). Less than 0.2% is excreted unchanged in urine.
Category C
Category C
Antifungal
Antifungal